Observational Study on the Efficacy of Empirical Antimicrobial Therapy in Febrile Neutropenia

What this Trial Is About

Researchers are evaluating the effectiveness and safety of a stepwise empirical anti-infective treatment for patients with blood cancers who develop febrile neutropenia, a condition involving fever and low white blood cell count. This open-label, single-arm clinical study focuses on a standardized treatment protocol that escalates therapy based on patient response. The study includes monitoring clinical symptoms, inflammatory markers, imaging results, and microbiological tests to assess treatment success. The treatment starts with carbapenem antibiotics given for 2 days. If fever persists, vancomycin or linezolid is added for 3 days. If there is still no improvement, antifungal therapy is introduced for 7 days. For patients with ongoing fever and uncontrolled infection after 12 to 14 days, the protocol switches to a combination of ceftazidime-avibactam and aztreonam. Treatment duration may be adjusted according to neutrophil recovery and fever status. Participants will undergo regular assessments including temperature monitoring, blood tests for inflammatory markers like C-reactive protein and procalcitonin, chest imaging to check lung infections, and microbiological cultures to identify pathogens. Safety is closely tracked through continuous monitoring of adverse events and mortality during the treatment course. The study aims to provide detailed data on symptom resolution and infection control over the therapy period.

Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.